|
⚲
|
| Keyboard |
| Soleus Capital LLC | |
|---|---|
| Firm | Soleus Capital Management LP |
| Address | 100 Field Point Road Suite 200 Greenwich, CT 06830 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Soleus Capital Management LP | |||||
| Soleus Capital Special Opportunities Fund LP | 021-347654 | Executive Officer | 10.8 M | 0.2 M | |
| Soleus Capital Master Fund LP | 021-321873 | Executive Officer | 583.9 M | 3,016.2 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Sell | 16,909 | $16.00 | 270,544 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Buy | 155,000 | $16.00 | 2,480,000 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 338,330 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 104,608 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Option exercise | 31,382 | $8.63 | 270,827 |
|
Lyra Therapeutics Inc LYRA
Series B Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 11,666,666 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock Warrant · derivative
|
2020-05-05 | Option exercise | 31,382 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Series C Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 3,607,224 | $0.00 |